FMP
Globus Medical, Inc.
GMED
NYSE
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
90.8 USD
0.33 (0.363%)
Zacks Investment Research
Aug 22, 2024
Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.
Zacks Investment Research
Aug 9, 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research
Aug 8, 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research
Aug 7, 2024
Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.
Seeking Alpha
Aug 6, 2024
Globus Medical, Inc. (NYSE:GMED ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Daniel Scavilla - President and CEO Keith Pfeil - COO and CFO Conference Call Participants Matthew Miksic - Barclays Vikramjeet Chopra - Wells Fargo Shagun Singh - RBC CM Steve Lichtman - Oppenheimer David Saxon - Needham & Company Matthew O'Brien - Piper Sandler Jason Wittes - ROTH Matthew Blackman - Stifel Ryan Zimmerman - BTIG Ravi M...
Zacks Investment Research
Aug 6, 2024
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research
Aug 6, 2024
Globus Medical (GMED) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.63 per share a year ago.
Zacks Investment Research
Jul 19, 2024
In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.
Zacks Investment Research
Jul 18, 2024
Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.
GlobeNewsWire
Jul 16, 2024
AUDUBON, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 6, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.